Abstract: The invention provides a method of treating a patient having target cells that express Fc?RIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding Fc?RIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and Fc?RIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of Fc?RIIb.

Abstract: Described is the use of a first antibody molecule that specifically binds Fc?RIIb via its Fab region, but lacks Fc region or has reduced binding to Fc? receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on an immune cell, wherein the immune cell is an immune cell that suppresses anti-cancer immunity, which second antibody molecule has an Fc region that binds to at least one activating Fc? receptor, and wherein the binding of the second antibody molecule to the receptor on the immune cell causes depletion and/or deactivation of the immune cell in the treatment of an Fc?RIIb-negative cancer in a patient, as well as pharmaceutical compositions and kits comprising these to antibody molecules, and methods of treating cancer using these two antibodies.

Abstract: The invention provides a method of treating a patient having target cells that express Fc?RIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding Fc?RIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and Fc?RIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of Fc?RIIb.

Abstract: The present invention relates to a composition comprising an antibody molecule and an agent for use in the treatment of refractory cancer and/or relapsed cancer. The invention also relates to a method of treating refractory cancer and/or relapsed cancer comprising administering an antibody molecule and an agent. There are also described kits comprising the antibody molecule and agents.

Abstract: Described is the use of a first antibody molecule that specifically binds Fc?RIIB via its Fab region, but lacks Fc region or has reduced binding to Fc? receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on a tumor cell, which second antibody molecule has an Fc region that binds to at least one activating Fc? receptor in the treatment of an Fc?RIIB-negative cancer in a patient, as well as pharmaceutical compositions and kits including these two antibody molecules, and methods of treating cancer using these two antibodies.

Abstract: Described is the use of a first antibody molecule that specifically binds Fc?RIIb via its Fab region, but lacks Fc region or has reduced binding to Fc? receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on an immune cell, wherein the immune cell is an immune cell that suppresses anti-cancer immunity, which second antibody molecule has an Fc region that binds to at least one activating Fc? receptor, and wherein the binding of the second antibody molecule to the receptor on the immune cell causes depletion and/or deactivation of the immune cell in the treatment of an Fc?RIIb-negative cancer in a patient, as well as pharmaceutical compositions and kits comprising these to antibody molecules, and methods of treating cancer using these two antibodies.

Abstract: Description of a composition comprising an antibody molecule and an agent for use in the treatment of refractory cancer and/or relapsed cancer, and of a method of treating refractory cancer and/or relapsed cancer comprising administering an antibody molecule and an agent. There are also described kits comprising the antibody molecule and agents.

Abstract: The present invention generally relates to antibody combinations and uses thereof.

Abstract: The invention provides a method of treating a patient having target cells that express Fc?RIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding Fc?RIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and Fc?RIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of Fc?RIIb.

Abstract: The invention provides a method of treating a patient having target cells that express Fc?RIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding Fc?RIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and Fc?RIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of Fc?RIIb.

Abstract: Described is the combined use of a first antibody molecule that specifically binds FcyRIIb via its Fab region and that binds an Fey receptor via its Fc region, and a second antibody molecule that specifically binds PD-1 and that binds at least one Fey receptor via its Fc region, in the treatment of cancer in a patient having tumor infiltrating T lymphocytes with a medium or high PD-1 expression, as well as pharmaceutical compositions and kits comprising these two antibody molecules, and methods of treating cancer using these two antibodies. Described is also a diagnostic test for identification of patients benefitting from the treatment described herein.

Abstract: The invention provides a method of treating a patient having target cells that express Fc?RIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding Fc?RIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and Fc?RIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of Fc?RIIb.

Abstract: Described is the use of a first antibody molecule that specifically binds Fc?RIIb via its Fab region, but lacks Fc region or has reduced binding to Fc? receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on an immune cell, wherein the immune cell is an immune cell that suppresses anti-cancer immunity, which second antibody molecule has an Fc region that binds to at least one activating Fc? receptor, and wherein the binding of the second antibody molecule to the receptor on the immune cell causes depletion and/or deactivation of the immune cell in the treatment of an Fc?RIIb-negative cancer in a patient, as well as pharmaceutical compositions and kits comprising these to antibody molecules, and methods of treating cancer using these two antibodies.

Abstract: The invention provides a method of treating a patient having target cells that express Fc?RIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding Fc?RIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and Fc?RIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of Fc?RIIb.

Abstract: The invention provides a method of treating a patient having target cells that express FcyRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcyRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcyRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcyRIIb.

Abstract: Description of a composition comprising an antibody molecule and an agent for use in the treatment of refractory cancer and/or relapsed cancer, and of a method of treating refractory cancer and/or relapsed cancer comprising administering an antibody molecule and an agent. There are also described kits comprising the antibody molecule and agents.

Abstract: The invention provides a method of treating a patient having target cells that express FcyRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcyRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcyRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcyRIIb.